Salem students among young innovators honored in national science competition
PORTLAND, Ore. (KOIN) — Some of the most brilliant young minds in America have gone head-to-head to produce groundbreaking inventions, and those creations will be honored in a special awards ceremony.
The annual Toshiba/NSTA ExploraVision Challenge is considered the world's largest K-12 science competition award.
Students from Heritage School in Salem are among the young innovators being honored.
Host Justin Shaifer, also known as 'Mr. Fascinate,' joined us on AM Extra to go over the incredible inventions students have come up with.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Educators learn to use AI tools at Niswonger School Success Symposium
KINGSPORT, Tenn. (WJHL) – At this year's Niswonger Foundation School Success Symposium, teachers from around East Tennessee gathered to learn more about changing technology in the classroom, including the uses of AI. Niswonger Foundation CEO Steve Barnett said the topic of the symposium was chosen by the teachers attending. This year, Barnett said teachers decided to learn about how AI tools can be used in the classroom. 'It's emerging and it's going to continue to change over time,' Barnett said. 'And we want to make sure that it's something that teachers feel comfortable with because they see your students use it, teachers can use it and we want to make sure everybody has what they need to be able to be successful with our use of AI in the classroom.' 2024 National Teacher of the Year Missy Testerman spoke to over 600 teachers about how even though AI will change things, human connection with students will always be needed. Testerman said, for example, AI tools will not help students who may be nervous about a test. 'It is something that we're going to have to embrace because we want our students to be prepared for the future,' Testerman said. 'We just have to figure out a way to take in all the advantages that we can of ed tech while we maintain that spirit of humanity.' Live music, kids fishing day and more | Weekend events in the Tri-Cities Beth Zeisenis, also known as 'Beth Z, Your Nerdy Best Friend,' was this year's keynote speaker for the symposium. 'Teachers have such a tough time right now with the whole concept of AI and so what I tried to do was give them some tools that they can use right away, plus some bigger concepts about how it works and where it's going,' Zeisenis said. Zeisenis went through many AI programs including Chat GPT and Magic School Plus. She said teachers can use AI tools to complete small tasks such as making lesson plans. Zeisenis also said teachers need to have conversations with students about how to properly use AI instead of trying to stop students from using it altogether. 'We need to go into conversations with our students about trusting each other and about learning this together, because if we go in with a defensive posture, if we go in distrusting each other, then you have a challenge because it's there all the time,' Zeisenis SAID. 'It's going to be like calculators in our pockets. They're going to have it for the rest of their lives. So how can we teach students and each other how we can use that rather than being afraid of it or feeling like it's an affront to what's going on?' Zeisenis and Testerman both encourage East Tennessee teachers to talk to school administrators about the ways AI can be used in the classroom. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
10 hours ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Young minds dive into discovery at Pfizer School of Science Mobile Experience
MALL OF AMERICA (WLAX/WEUX) – Science came to life as curious young minds took center stage at the Pfizer School of Science Mobile Experience, a hands-on educational adventure designed to spark curiosity and inspire future scientists. Located in the North Lot of Mall of America, the immersive event welcomed kids aged 8–14 to step into the shoes of real scientists. From decoding complex clues to solving science-themed riddles, participants raced against the clock in a fully interactive escape room environment. The goal? To demonstrate that science isn't just something you read about—it's something you do. The Mobile Experience is part of Pfizer's broader School of Science initiative, an educational program aimed at igniting a passion for the life sciences in students at an early age. By combining play with problem-solving, the initiative helps demystify complex scientific concepts and makes learning genuinely fun. During these half-day field trips, students explore Pfizer's work through hands-on labs and 90-minute instructional courses covering topics like Drug Discovery, Microbiology, and Immunology. They'll also meet Pfizer professionals, gaining a real-world perspective on the impact and possibilities of a career in science. As both a mobile and in-office program, Pfizer School of Science is more than an outreach effort—it's a commitment to shaping the next generation of innovators, thinkers, and problem-solvers. With every clue cracked and every question asked, Pfizer is helping young people see that science is not just a subject, but a gateway to change the world. Whether in a mobile lab or a Manhattan office, the Pfizer School of Science is proving one thing: the future of discovery starts now. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
